Effect of particle deposition density of dry powders on the results produced by an in vitro test system simulating dissolution- and absorption rates in the lungs-Reference-Cited by-同舟云学术

Effect of particle deposition density of dry powders on the results produced by an in vitro test system simulating dissolution- and absorption rates in the lungs

Published:2019-06 Issue: Volume:139 Page:213-223
ISSN:0939-6411
Container-title:European Journal of Pharmaceutics and Biopharmaceutics
language:en
Short-container-title:European Journal of Pharmaceutics and Biopharmaceutics

Author:

Malmlöf Maria,Nowenwik Mattias,Meelich Kristof,Rådberg Iwona,Selg Ewa,Burns John,Mascher Hermann,Gerde Per

Publisher

Elsevier BV

Subject

Pharmaceutical Science,General Medicine,Biotechnology

Reference31 articles.

1. In vitro testing for orally inhaled products: developments in science-based regulatory approaches;Forbes;AAPS J.,2015

2. Challenges with developing in vitro dissolution tests for orally inhaled products (OIPs);Riley;AAPS PharmSciTech.,2012

3. Dry powder inhalers: an overview of the in vitro dissolution methodologies and their correlation with the biopharmaceutical aspects of the drug products;Velaga;Eur. J. Pharm. Sci.,2018

4. Comparison of two in vitro systems to assess cellular effects of nanoparticles-containing aerosols;Frohlich;Toxicol. In Vitro,2012

5. Dry powder inhalation exposures of the endotracheally intubated rat lung, ex vivo and in vivo: the pulmonary pharmacokinetics of fluticasone furoate;Selg;J. Aerosol. Med. Pulm Drug Deliv.,2013

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integration of mucus and its impact within in vitro setups for inhaled drugs and formulations: Identifying the limits of simple vs. complex methodologies when studying drug dissolution and permeability;International Journal of Pharmaceutics;2024-08

2. Regional lung targeting with a fluticasone/salmeterol aerosol using a bolus breath hold method of the PreciseInhale® system: A first evaluation in humans;European Journal of Pharmaceutical Sciences;2024-05

3. Reconstituted dry powder formulations of ZnO-adjuvanted ovalbumin induce equivalent antigen specific antibodies but lower T cell responses than ovalbumin adjuvanted with Alhydrogel® or cationic adjuvant formulation 01 (CAF®01);International Journal of Pharmaceutics;2023-12

4. Optimizing the design and dosing of dry powder inhaler formulations of the cationic liposome adjuvant CAF®01 for pulmonary immunization;Frontiers in Drug Delivery;2022-09-07

5. Bioavailability of inhaled or ingested PFOA adsorbed to house dust;Environmental Science and Pollution Research;2022-06-14